Questions

880. Deputy Erin McGreehan asked the Minister for Health the reason neither hospitals (details supplied) in Drogheda or Dundalk provides faecal immunochemical testing (FIT) for symptomatic patients; when it is intended to introduce the service in County Louth; and if she will make a statement on the matter. [53432/26]

881. Deputy Erin McGreehan asked the Minister for Health to provide, for each hospital currently providing faecal immunochemical testing (FIT) for symptomatic patients, the average waiting time from GP referral to FIT testing, together with the average waiting time from GP referral to colonoscopy following a positive FIT result, broken down by hospital site. [53433/26]

882. Deputy Erin McGreehan asked the Minister for Health whether her Department has assessed the impact of the absence of faecal immunochemical testing (FIT) services in County Louth on waiting times for suspected bowel cancer patients attending a hospital (details supplied) in Drogheda; and if she will provide the waiting time from GP referral to colonoscopy for those patients [53434/26]

883. Deputy Erin McGreehan asked the Minister for Health to provide, for each hospital currently providing faecal immunochemical testing (FIT) for symptomatic patients, the average, median and longest waiting time from GP referral to FIT testing and GP referral to colonoscopy following a positive FIT result, broken down by hospital site; and if she will make a statement on the matter. [53435/26]

898. Deputy Erin McGreehan asked the Minister for Health her plans to consider GLP1 drugs to be included under the drugs payments scheme for persons prescribed it for medical conditions other than diabetes for example polycystic ovary syndrome (PCOS); and if she will make a statement on the matter. [53573/26]

776. Deputy Erin McGreehan asked the Minister for Health the public care available to women who wish to have their hormones tested on an asymptomatic basis; and if she will make a statement on the matter. [51178/26]

545. Deputy Erin McGreehan asked the Minister for Health the status of the proposed EU Common Training Framework (CTF) for physiotherapists; if her Department or CORU has taken a formal position on its potential introduction; the measures being considered to ensure that any future regulatory framework maintains patient safety and professional standards, particularly in light of variations in physiotherapy training ac…

292. Deputy Erin McGreehan asked the Minister for Health when it was decided by her Department and agreed with the Health Research Consent Declaration Committee (HRCDC) that persons making applications to the Minister for membership of the Committee would be informed that they must instead make their applications through the Committee; if that agreement was formally recorded by the Department and the HRCDC: if the ar…

293. Deputy Erin McGreehan asked the Minister for Health whether her Department considered the data protection implications of the arrangement with the Health Research Consent Declaration Committee (HRCDC) whereby it requires applicants for membership of the Committee to provide their personal data to the Committee without a statutory basis for that requirement. [49988/26]

294. Deputy Erin McGreehan asked the Minister for Health the reason the Health Research Consent Declaration Committee is able to periodically publicly invite expressions of interest for membership of the committee. [49989/26]

309. Deputy Erin McGreehan asked the Minister for Health the current status of the health technology assessment and reimbursement decision for pluvicto (lutetium-177 PSMA therapy) for the treatment of metastatic castration-resistant prostate cancer; the timeline for a final determination; and if she will make a statement on the matter. [50111/26]

310. Deputy Erin McGreehan asked the Minister for Health the steps being taken to ensure Irish patients have timely and equitable access to innovative oncology treatments, including radioligand therapies such as pluvicto; and the way Ireland compares with other EU Member States in access to such treatments. [50112/26]

311. Deputy Erin McGreehan asked the Minister for Health the current capacity within the public health system to deliver radioligand therapies, including the availability of nuclear medicine facilities, trained personnel, and radiopharmacy supports; and the plans in place to expand this capacity. [50113/26]

312. Deputy Erin McGreehan asked the Minister for Health whether her Department has undertaken or commissioned any strategic review of Ireland's nuclear medicine and radiopharmacy infrastructure; and the actions planned to develop a sustainable, indigenous capability in this area. [50114/26]

313. Deputy Erin McGreehan asked the Minister for Health if consideration is being given to developing a national strategy for radiopharmaceutical production and usage, in light of increasing global demand and supply constraints; and if she will outline any engagement with industry, academia, or international partners on this issue. [50115/26]

314. Deputy Erin McGreehan asked the Minister for Health the level of capital and operational investment allocated to nuclear medicine and advanced cancer therapies over the past five years; and the projected investment over the next five years to support emerging treatments such as radioligand therapies. [50116/26]

315. Deputy Erin McGreehan asked the Minister for Health the current number of specialists in nuclear medicine, radiopharmacy, and medical physics in Ireland; the projected workforce requirements to support expansion in radioligand therapies; and the plans to address any identified gaps. [50117/26]

316. Deputy Erin McGreehan asked the Minister for Health the supports in place to enable Irish participation in international clinical trials involving radiopharmaceuticals and targeted radionuclide therapies; and the way in which Ireland can position itself as a hub for such research. [50118/26]

317. Deputy Erin McGreehan asked the Minister for Health the extent of engagement with patient advocacy organisations, including those representing prostate cancer patients, in relation to the reimbursement and provision of new treatments such as pluvicto. [50119/26]

318. Deputy Erin McGreehan asked the Minister for Health if she will support a dedicated session of the relevant Oireachtas Committee to examine the case for investment in nuclear medicine and radiopharmacy infrastructure, including emerging cancer therapies; and if officials from her Department would be available to attend. [50120/26]

319. Deputy Erin McGreehan asked the Minister for Health if she will provide an update on the review of the operation of Drogheda Cottage Hospital; when this review is expected to be completed; and if she can give assurances that the hospital will remain open. [50125/26]

501. Deputy Erin McGreehan asked the Minister for Health her views on the role of innovative medicines, national registries and other key system enablers in informing the development of the next National Cancer Strategy; and if she will make a statement on the matter. [48649/26]

739. Deputy Erin McGreehan asked the Minister for Health the status of negotiations regarding belzutifan, noting that the HSE is currently engaged in pricing discussions with a company (details supplied).; and if she will make a statement on the matter. [47251/26]

177. Deputy Erin McGreehan asked the Minister for Health when the National Cancer Strategy Implementation Reports for 2024 and 2025 will be published; and if she will make a statement on the matter. [45981/26]

178. Deputy Erin McGreehan asked the Minister for Health when the evaluation for the National Cancer Strategy 2017-2026 will commence; and if she will make a statement on the matter. [45982/26]